All Blogs

Sep 05, 2016

Recent Pharma Developments related to Immune Checkpoint Activators


Sep 02, 2016

Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys; Insys marketed drug


Sep 01, 2016

Identity Crises Faced by a Venerable Brain-Cancer Cell Line


Aug 31, 2016

BI & Duke Clinical Research Institute have expansion; BioInvent Inks Mfg. Pact; Elite Pharma, SunGen Pharma in Development & License Deal; Boehringer and Saniona Develop new Compounds; BioLineRx and I-Bridge Capital Establish; Alliance between Harvard and Tata Companies; Innovative Targeting Solutions and Johnson & Johnson Innovation collaborate


Aug 30, 2016

The Road Less Travelled: EpiPen’s Pricing Policy


Aug 26, 2016

Denali’s Impressive Research Portfolio


Aug 25, 2016

NATCO Pharma surges; AstraZeneca falls; US patent office rules


Aug 24, 2016

Bristol Meyers Squibb & AbbVie partner; BioLineRx’s collaboration with MD Anderson Cancer Centre; Partnership between Regeneron Pharmaceuticals and Adicet Bio; Immunotherapy Target Unique Mutations in cancer


Aug 23, 2016

The Curious Case of CRISPR Technology


Aug 22, 2016

Nav1.7 Blockers- New Genre of Pain Relief Therapy